Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Endokrynologia Polska|September 29, 2006
[Indications for surgery of thyroid cancer based on bioptate molecular examination]Elzbieta Gubała, Tomasz Olczyk, Agnieszka Pawlaczek, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2003
Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patientsBarbara Jarzab, Daria Handkiewicz-Junak, Józef Roskosz, et al.
The Journal of Clinical Endocrinology and Metabolism|September 24, 2009
Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective studyMarkus Luster, Daria Handkiewicz-Junak, Armando Grossi, et al.
Thyroid Research|August 4, 2009
13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 studyDaria Handkiewicz-Junak, Jozef Roskosz, Kornelia Hasse-Lazar, et al.
Thyroid : Official Journal of the American Thyroid Association|September 25, 2024
Changing Clinical Presentation of Pediatric Differentiated Thyroid Cancer in Poland: A Retrospective Cohort Study Spanning 45 YearsAleksandra Kropinska, Aleksandra Ledwon, Ewa Paliczka Cieslik, et al.
Endokrynologia Polska|January 17, 2014
Neuroendocrine neoplasms of the small intestine and the appendix - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours)Marek Bolanowski, Tomasz Bednarczuk, Barbara Bobek-Billewicz, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomasLisa Bodei, Daria Handkiewicz-Junak, Chiara Grana, et al.
Annals of Nuclear Medicine|August 7, 2021
Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancerAleksandra Ledwon, Ewa Paliczka-Cieślik, Aleksandra Syguła, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 3, 2022
In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapyAleksandra Syguła, Aleksandra Ledwon, Kornelia Hasse-Lazar, et al.
Nuclear Medicine and Molecular Imaging|November 15, 2019
Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid CarcinomaJolanta Krajewska, Michal Jarzab, Aleksandra Kukulska, et al.
Pageof 8